Esperion announced the European Commission approved the Nustendi (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hypercholesterolemia and dyslipidemia in Europe. Nustendi… read more.
Novo Nordisk announced that the European Commission (EC) has granted marketing authorisation for Rybelsus (oral semaglutide), for the treatment of adults with insufficiently controlled type 2 diabetes to… read more.
The pivotal Phase III clinical trial results announced show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) from Sanofi + Regeneron ,in children aged 6-11 years with uncontrolled… read more.
Xarelto ( rivaroxaban) reduced the risk of major venous thromboembolism (VTE) by about 75% in adult patients during a period of immobilization after nonmajor lower limb orthopaedic surgery,… read more.
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed Brilinta (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12… read more.
The majority of patients with follicular lymphoma (FL) have excellent results when treated with chemotherapy so — even with evolving understanding of disease biology and availability of a parade… read more.
Professor Stephen Ansell (Rochester, USA) discusses the DIAL study
Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.
Dr Alison J. Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins
Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
